Literature DB >> 24689950

The relation between carotid intima media thickness and serum osteoprotegerin levels in nonalcoholic fatty liver disease.

Teslime Ayaz1, Aynur Kirbas, Tugba Durakoglugil, Murtaza Emre Durakoglugil, Serap Baydur Sahin, Osman Z Sahin, Abdulkadir Kirvar, Filiz Tasci.   

Abstract

AIM: This study was designed to evaluate carotid intima media thickness (CIMT) and serum osteoprotegerin (OPG) levels in nonalcoholic fatty liver disease (NAFLD) in comparison to healthy controls and to investigate factors predicting the CIMT increase.
MATERIALS AND METHODS: A total of 60 outpatients [median (min-max) age 44.5 (24.0-65.0) years, 63.3% were females] diagnosed with NAFLD via ultrasonography performed during their admission to our hospital for any reason and 30 control subjects [median (min-max) age 39.5 (24.0-57.0) years, 73.3% were females] with normal liver echogenicity in ultrasonography were included in this study. Data on demographic characteristics, anthropometric measurements, biochemical and hematological tests, CIMT measurement, serum levels for OPG, and predictive factors for the CIMT increase were collected.
RESULTS: Median (min-max) CIMT [0.60 (0.40-1.10) vs. 0.50 (0.30-0.60), P<0.001) and OPG (pg/mL) [65.0 (18.1-272.8) vs. 32.0 (10.1-82.3), P<0.001] levels were significantly higher in NAFLD patients compared to controls, while there was a significant positive correlation between CIMT and serum OPG (r=0.42, P<0.001). Mean CIMT value was determined to increase significantly by 0.001 cm (P=0.001) for each 1 pg/mL of increase in OPG levels, by 0.103 cm (P<0.001) in case of concomitant NAFLD (P<0.001), and by 0.006 cm (P<0.001) for each 1 pg/mL of increase in urea levels.
CONCLUSION: Our findings indicate higher levels of serum OPG and CIMT in patients with NAFLD compared to controls along with a positive correlation between serum OPG and CIMT levels. High levels of serum OPG, presence of NAFLD, and high levels of serum urea seem to be the independent risk factors predictive for the CIMT increase.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24689950     DOI: 10.1089/met.2013.0151

Source DB:  PubMed          Journal:  Metab Syndr Relat Disord        ISSN: 1540-4196            Impact factor:   1.894


  5 in total

1.  Association of serum osteoprotegerin with severity of chronic liver disease in female patients: A potential biomarker.

Authors:  Saba Tariq; Sundus Tariq; Shaista Hussain; Mukhtiar Baig
Journal:  Pak J Med Sci       Date:  2020 Sep-Oct       Impact factor: 1.088

2.  Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals.

Authors:  Ansel Shao Pin Tang; Kai En Chan; Jingxuan Quek; Jieling Xiao; Phoebe Tay; Margaret Teng; Keng Siang Lee; Snow Yunni Lin; May Zin Myint; Benjamin Tan; Vijay K Sharma; Darren Jun Hao Tan; Wen Hui Lim; Apichat Kaewdech; Daniel Huang; Nicholas Ws Chew; Mohammad Shadab Siddiqui; Arun J Sanyal; Mark Muthiah; Cheng Han Ng
Journal:  Clin Mol Hepatol       Date:  2022-03-02

3.  Association of Osteoprotegerin with Obesity, Insulin Resistance and Non-Alcoholic Fatty Liver Disease in Children.

Authors:  Meltem Erol; Ozlem Bostan Gayret; Hikmet Tekin Nacaroglu; Ozgul Yigit; Oguzhan Zengi; Mehmet Salih Akkurt; Mehmet Tasdemir
Journal:  Iran Red Crescent Med J       Date:  2016-11-01       Impact factor: 0.611

Review 4.  Role of osteoprotegerin/receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappa B ligand axis in nonalcoholic fatty liver disease.

Authors:  Lucia Pacifico; Gian Marco Andreoli; Miriam D'Avanzo; Delia De Mitri; Pasquale Pierimarchi
Journal:  World J Gastroenterol       Date:  2018-05-21       Impact factor: 5.742

5.  Association between non-alcoholic fatty liver disease and subclinical atherosclerosis in Western and Asian cohorts: an updated meta-analysis.

Authors:  Mark Yu Zheng Wong; Jonathan Jiunn Liang Yap; Rehena Sultana; Mark Cheah; George Boon Bee Goh; Khung Keong Yeo
Journal:  Open Heart       Date:  2021-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.